All In Biotech

Drug Trial Radar · NCT06191263

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Jan 5, 2024

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Ryvu Therapeutics SAIndustry
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2

Conditions

  • Acute Myeloid Leukemia

Interventions

  • RVU120Drug

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

  • VenetoclaxDrug

    Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Part 1) recommended doses of RVU120 and venetoclax for further studyTime frame: approx. 12 months
  2. (Parts 2 & 3) CR/CRh rate (Complete Remission/Complete Remission with incomplete Hematologic Recovery)Time frame: approx. 36 months

Locations

37 sites in 4 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire Grenoble Alpes

    Grenoble, France · Recruiting

  • Centre Hospitalier Le Mans

    Le Mans, France · Recruiting

  • Centre Hospitalier Universitaire De Lille

    Lille, France · Recruiting

  • Institut Paoli-Calmettes

    Marseille, France · Recruiting

  • Centre Hospitalier Universitaire De Nice

    Nice, France · Recruiting

  • Centre Hospitalier Universitaire De Nimes

    Nîmes, France · Recruiting

  • Assistance Publique Hopitaux De Paris

    Paris, France · Recruiting

  • Centre Henri Becquerel

    Rouen, France · Recruiting

  • Azienda Ospedaliero Universitaria Delle Marche

    Ancona, Italy · Recruiting

  • Univerisity of Bologna Policlinico Sant'Orsola

    Bologna, Italy · Recruiting

  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

    Brescia, Italy · Recruiting

  • Ospedale Vito Fazzi Lecce

    Lecce, Italy · Recruiting

  • AUSL Romagna - Ospedale S.M. Delle Croci

    Ravenna, Italy · Recruiting

  • Azienda Ospedaliera Policlinico Universitario Tor Vergata

    Roma, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino

    Turin, Italy · Recruiting

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Forlì-Cesena, Italy · Recruiting

  • Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej

    Biała Podlaska, Poland · Terminated

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland · Recruiting

  • PRATIA Onkologia Katowice

    Katowice, Poland · Recruiting

  • Wojewodzki Szpital Zespolony Im.L.Rydygiera w Toruniu

    Torun, Poland · Terminated

  • Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego

    Wałbrzych, Poland · Recruiting

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland · Recruiting

  • Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy

    Warsaw, Poland · Terminated

  • Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii

    Wroclaw, Poland · Recruiting

  • Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.

    Zielona Góra, Poland · Terminated

  • MTZ Clinical Research

    Warsaw, Mazowieckie Województwo, Poland · Recruiting

  • Hospital Del Mar

    Barcelona, Spain · Recruiting

  • Hospital De La Santa Creu I Sant Pau

    Barcelona, Spain · Recruiting

  • Institut Catala D'oncologia

    Barcelona, Spain · Not yet recruiting

  • Hospital San Pedro De Alcantara

    Cáceres, Spain · Recruiting

  • MD Anderson Cancer Center

    Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario Regional De Malaga

    Málaga, Spain · Recruiting

  • Clinica Universidad De Navarra

    Pamplona, Spain · Recruiting

  • University Hospital Virgen Del Rocio S.L.

    Seville, Spain · Recruiting

  • Hospital Universitario Y Politecnico La Fe

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.